Oramed製藥 ORMP 深 滬
等待開盤 04-03 09:30:00 美东时间
3.41
+0.020
+0.59%
華盛通- 最 高3.44
- 今 開3.33
- 成交量 3.44万股
- 最 低 3.31
- 昨 收 3.39
- 總市值 1.38亿
- 52周最高 3.76
- 市盈率 靜 2.27
- 換手率 0.09%
- 52周最低 1.725
- 委 比 -91.18%
- 總股本 4044.62万
- 歷史最高 31.48
- 量 比 0.46
- 振 幅 3.83%
- 歷史最低 -0.05
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed
03-26 04:17
Lifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Ltd. announced the closure of its strategic partnership with Oramed Pharmaceuticals Inc., acquiring Oramed's POD™ technology and securing up to $47 million in capital, with $10 million accessed. The partnership aims to diversify Lifeward's biomedical portfolio and enhance profitability, supporting its mission to innovate for individuals with physical limitations.
03-25 20:10
Lifeward Shareholders Approve Issuance Of Ordinary Shares Over Previously Announced Collaboration Deal With Oramed Pharmaceuticals
Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its
03-13 20:03
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Lifeward Ltd. shareholders approved a strategic partnership with Oramed Pharmaceuticals Inc., integrating Oramed’s POD™ oral delivery technology and accessing up to $47 million in capital. The partnership aims to strengthen Lifeward’s path to profitability while expanding into biotech markets. Lifeward will focus on three core priorities: driving profitability from its MedTech portfolio, selectively investing in innovative technologies, and build...
03-13 12:00
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal
The latest announcement is out from Oramed Pharm ( ($ORMP) ). On February 19, 2...
02-21 05:53
The top-performing pharma and biotech stocks as group sees resurgence
Pharmaceutical (PJP), (XPH), (PPH) and biotechnology stocks (XBI), (BBH) have officially returned to favor on Wall Street, according to Michael Yee, global head of biotechnology equity research at UBS...
02-14 03:01
UPDATE: Lifeward To Acquire Oramed's POD Technology And Secure Up To $47M Strategic Investment As Oramed Takes Up To 49.99% Stake
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder
01-13 21:18
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward ...
01-13 20:58
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Lifeward Ltd has secured up to $47 million in strategic investment from Oramed Pharmaceuticals and another investor to drive profitability and diversify its portfolio into biotech. Lifeward acquired Oramed's Protein Oral Delivery (POD™) technology, targeting the $600+ billion injectable drugs market, including the potential first oral insulin medicine, ORMD-0801. The transaction allows Lifeward to focus on existing MedTech products like ReWalk an...
01-13 13:00
Oramed Pharm Announces Dividend After Scilex Payment Gain
Oramed Pharm ( ($ORMP) ) has provided an update. On January 7, 2026, Oramed Pha...
01-07 22:17
